Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Researchers compared regimens prescribed to pregnant women in their second trimester.
The country’s National Health Service will pay for the drug as part of its goal to end HIV transmission by 2030.
Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.
This is especially the case for people globally who don’t have access to such newer regimens.
Who owns the rights to PrEP? The U.S. government or the pharma giant?
They would follow the lead of California, which allows pharmacies to dispense a 30-day supply of the HIV prevention pill without a script.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Canadian researchers analyzed the reasons why people declined a nurse’s offer of PrEP.
Both Truvada and Descovy are highly effective and safe for most people taking PrEP, but the newer option has more cost barriers.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Plus: Tell your representatives to support the PrEP Access and Coverage Act. Here’s how.
This PrEP dosing strategy involves taking doses of Truvada only during the days surrounding sex.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.